Status:
COMPLETED
Efficacy of Combination Immunotherapy in Patients With Metastatic Colorectal Cancer
Lead Sponsor:
First Affiliated Hospital of Zhejiang University
Conditions:
Colorectal Cancer
Eligibility:
All Genders
Phase:
PHASE2
Brief Summary
Immunotherapy improved efficacy and survival in selective patients with metastatic colorectal cancer (mCRC), however, limited data revealed the landscape of immunotherapy efficacy. What's more, potent...
Eligibility Criteria
Inclusion
- patients who had both baseline measurable lesion(s) and at least one post-baseline radiological disease reassessment
- patients with identified genomic status
Exclusion
- patients who received immune monotherapy
- patients who stopped treatment for any reason without identified response assessment.
Key Trial Info
Start Date :
March 10 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 30 2022
Estimated Enrollment :
97 Patients enrolled
Trial Details
Trial ID
NCT05414461
Start Date
March 10 2019
End Date
April 30 2022
Last Update
June 10 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The First Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, China, 310003